About: vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $25.86 (+0.54%)
VTVT NASDAQ vTv Therapeutics Inc
vTv Therapeutics Inc share price
Atividade de preço de VTVT
Último preço
$ 25,860
Variação (24h)
0,14 USD (0,54%)
Volume
1.07K
Volume (média 4 sem.)
-
Abertura
$ 26,17
Variação do dia
$ 25,86 - $ 26,17
Fechamento anterior
$ 25,72
Último negócio
29 Oct, 1:30 pm GMT+0
Atrasado
29 Oct, 1:30 pm GMT+0
VTVT price performance
Atrasado
29 Oct, 1:30 pm GMT+0
quote.marketSignals